Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) versus chemo (C)

被引：1

作者：

Moehler, M. ^{[1
]}

Wyrwicz, L. ^{[2
]}

Chen, C. ^{[3
]}

Davenport, E. ^{[4
]}

Wang, J. ^{[4
]}

Nathani, R. ^{[3
]}

Kondo, K. ^{[3
]}

Elimova, E. ^{[5
]}

机构：

[1] Johannes Gutenberg Univ Mainz, Mainz, Germany

[2] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[3] Bristol Myers Squibb, Princeton, NJ USA

[4] RTI Int, Res Triangle Pk, NC USA

[5] Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.04.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O-10

引用

页码：S185 / S185

页数：1

共 50 条

[21] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.
Janjigian, Yelena Y.
Moehler, Markus H.
Ajani, Jaffer A.
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Cleary, James M.
Elimova, Elena
Bruges, Ricardo Elias
Karamouzis, Michalis
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
McCraith, Stephen
Hu, Nan
Zhang, Jennifer
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 398 - 398
[22] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
Janjigian, Yelena Y.
Shitara, Kohei
Moehler, Markus H.
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda Silva Campos
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Maya, Ricardo Elias Bruges
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Amaya-Chanaga, Carlos
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 291 - 291
[23] Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC)
Sugarman, Ryan
Nunna, Sasikiran
Betts, Keith A.
Nie, Xiaoyu
Nguyen, Hiep
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[24] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Wang, Rui
Sullivan, Kendall
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 353 - 353
[25] First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
Liu, Tianshu
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Ruihua
Guo, Weijian
Qin, Shukui
Yang, Nong
Lu, Jianwei
Shitara, Kohei
Lei, Ming
Li, Mingshun
Bao, Nicole
Chen, Tian
Shen, Lin
INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (04) : 749 - 760
[26] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Wang, Rui
McCraith, Stephen
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 318 - 318
[27] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate
Moehler, Markus
Janjigian, Yelena Y.
Shitara, Kohei
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Bruges, Ricardo
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Chanaga, Carlos Amaya
Ajani, Jaffer A.
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 64 - 64
[28] Health-related quality of life (HRQoL) in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC) treated with nivolumab (N) plus chemotherapy (CT) or nivo plus ipilimumab (I) versus chemo: Results from CheckMate 648
Bridgewater, John A.
Chau, Ian
Gricar, Joseph
Blum, Steven I.
Taylor, Fiona
Lawrance, Rachael
Padilla, Brad
Yip, Christine
Wyrwicz, Lucjan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[29] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Hu, Nan
McCraith, Stephen
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 392 - 392
[30] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/ gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4year (y) follow-up (FU) of CheckMate 649
Wyrwicz, L. S.
Shitara, K.
Moehler, M.
Ajani, J. A.
Shen, L.
Garrido, M.
Gallardo Araneda, C. E.
Yamaguchi, K.
Cleary, J.
Elimova, E.
Bruges Maya, R.
Karamouzis, M. V.
Skoczylas, T.
Bragagnoli, A. C.
Liu, T.
Tehfe, M.
Feeney, K.
Wang, R.
Zhang, J.
Janjigian, Y. Y.
ANNALS OF ONCOLOGY, 2024, 35 : S169 - S170

← 1 2 3 4 5 →